Sean David to Tobacco Use Disorder
This is a "connection" page, showing publications Sean David has written about Tobacco Use Disorder.
Connection Strength
2.027
-
Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 2008 Nov 01; 98(1-2):77-85.
Score: 0.282
-
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33.
Score: 0.265
-
Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol Psychiatry. 2005 Sep 15; 58(6):488-94.
Score: 0.230
-
Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019 02; 51(2):237-244.
Score: 0.147
-
From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics. 2018 07 01; 19(10):861-871.
Score: 0.141
-
Teaching Medical Students to Help Patients Quit Smoking: Outcomes of a 10-School Randomized Controlled Trial. J Gen Intern Med. 2016 Feb; 31(2):172-181.
Score: 0.120
-
Medical school curriculum characteristics associated with intentions and frequency of tobacco dependence treatment among 3rd year U.S. medical students. Prev Med. 2015 Mar; 72:56-63.
Score: 0.111
-
Teaching tobacco dependence treatment and counseling skills during medical school: rationale and design of the Medical Students helping patients Quit tobacco (MSQuit) group randomized controlled trial. Contemp Clin Trials. 2014 Mar; 37(2):284-93.
Score: 0.104
-
Tobacco dependence treatment teaching by medical school clerkship preceptors: survey responses from more than 1,000 US medical students. Prev Med. 2013 Aug; 57(2):81-6.
Score: 0.099
-
The neuroeconomics of nicotine dependence: a preliminary functional magnetic resonance imaging study of delay discounting of monetary and cigarette rewards in smokers. Psychiatry Res. 2012 Apr 30; 202(1):20-9.
Score: 0.092
-
Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):7-13.
Score: 0.087
-
Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008 Jun; 65(6):683-93.
Score: 0.070
-
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7.
Score: 0.068
-
Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1065-9.
Score: 0.066
-
Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res. 2004 Oct; 6(5):769-76.
Score: 0.055
-
Pharmacogenetics. Prim Care. 2004 Sep; 31(3):543-59, ix.
Score: 0.054
-
Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. Nicotine Tob Res. 2018 03 06; 20(4):414-424.
Score: 0.035